Thank You
Thank you for your form submission! Please check your email inbox for additional information regarding your request.
We wanted to be certain and very accurate around what we produce in these documents that are submitted to health authorities. We want to deliver a draft through Artificial Intelligence that is 100% reliable and needs no further editing by human medical writers. That is what we have achieved with the Yseop collaboration.


Machine learning is a part of every aspect of Lilly’s future, from drug discovery to clinical trials to manufacturing to patient support. Yseop brings a novel approach to regulatory submissions and other reporting, and we see opportunities to bring Yseop’s technology to teams throughout the enterprise.


Yseop enables us to focus our discussions on action plans for the branch. Now we spend more time talking about sales performance rather than analyzing figures. It saves time for myself and my team.


The Yseop engine produces this commentary in less than a second. We are just scratching the surface with this technology.


With Yseop, we give clear explanations to our customers. The customer understands the decision and I have more time to focus on other opportunities. It's a real innovation!


Previous
Next
Resources
At the forefront of innovations and developments in AI and NLG.
- May 16, 2023
- Blog
A recent study in JAMA Internal Medicine compared physician versus AI chatbot responses to patient’s questions asked on a public social media forum. Tim Martin, Yseop’s Vice president of Product and Development was featured in USA Today discussing this topic further.
- May 9, 2023
- Blog
In this blog post, we’ve highlighted the latest generative AI trends, updates and news articles from the past month.
- May 3, 2023
- Blog
Listen to the next episode of AI Uncovered with Marjo Gazak.